2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Achinger, S. G. Articles by Ayus, J. C. Search for Related Content PubMed PubMed Citation Articles by Achinger, S. G. Articles by Ayus, J. C.

Left Ventricular Hypertrophy: Is Hyperphosphatemia among Dialysis Patients a Risk Factor?

Texas Diabetes Institute, Bexar County Hospital District, San Antonio, Texas

Address correspondence to: Dr. Juan Carlos Ayus, Medical Director, Dialysis Service, Texas Diabetes Institute, University Dialysis West, 701 S. Zarzamora, San Antonio, TX 78201. Phone: 713-795-9333; Fax: 713-942-9342; E-mail: carlosayus{at}yahoo.com

Cardiovascular disease occurs in ESRD patients at rates that are far higher than is seen in the general population, and cardiovascular deaths account for the majority of deaths among dialysis patients. Abnormal mineral metabolism is a novel cardiovascular risk factor among dialysis patients. Recently published results demonstrated that even with good control of BP and anemia, conventional hemodialysis is associated with significant left ventricular hypertrophy (LVH); however, daily hemodialysis was associated with a significant reduction in LV mass index (LVMI). Furthermore, it was shown that control of serum phosphorus correlates with the reduction in LVMI. These data suggest a novel mechanism for the deleterious effect of elevated serum phosphorus on cardiovascular outcomes among hemodialysis patients: LVH. Other investigators have noted an association of hyperphosphatemia and LVH; however, this study was the first to demonstrate that improvement in serum phosphorus is associated with reduction in LVM. In addition, it is shown that daily hemodialysis is an effective modality in improving serum phosphorus through significantly improved phosphorus removal. Elevated serum phosphorus leads to vascular calcification, which can lead to LVH by decreasing vascular compliance. However, our study showed an improvement in LVMI during a 12-mo period. Because vascular calcification is unlikely to remit over this time period, it is proposed that serum phosphorus has a reversible, cardiotoxic effect that leads to LVH that can be reversed successfully with good control of serum phosphorus.

This article has been cited by other articles:

				J. F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros, H. Herrera, and J. Garcia Mineral Metabolism and Inflammation in Chronic Kidney Disease Patients: A Cross-Sectional Study Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1646 - 1654. [Abstract] [Full Text] [PDF]

				C. S Shinaberger, S. Greenland, J. D Kopple, D. Van Wyck, R. Mehrotra, C. P Kovesdy, and K. Kalantar-Zadeh Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am. J. Clinical Nutrition, December 1, 2008; 88(6): 1511 - 1518. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673